Table 1 Epidemiological and clinical characteristics of n = 10 independent pediatric patients confirmed with SARS-CoV-2 infection
Characteristics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 |
|---|---|---|---|---|---|---|---|---|---|---|
Age (months) | 74 | 151 | 85 | 165 | 14 | 41 | 188 | 164 | 2 | 21 |
Sex | Male | Female | Female | Male | Male | Male | Female | Male | Female | Male |
Exposure history | ||||||||||
Travel to Wuhan city | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✓ | ✓ | ✓ |
Travel to other cities of Hubei provincial | ✗ | ✓ | ✓ | ✗ | ✗ | ✗ | ✓ | ✓ | ✗ | ✗ |
Contact with person with 2019-nCoV | ✗ | ✗ | ✗ | ✓ | ✓ | ✓ | ✗ | ✗ | ✓ | ✗ |
Having family cluster outbreak | ✗ | ✓ | ✓ | ✓ | ✓ | ✓ | ✗ | ✗ | ✓ | ✓ |
Signs and symptoms at admission | ||||||||||
Fever (maximum, duration) | 39.1 °C, 23 h | 39.2 °C, 5 d | 38.4 °C, 3 d | ✗ | 37.8 °C, 3 h | ✗ | 38.5 °C, 1 h | 38.5 °C, 1 d | ✗ | 38.0 °C, 30 min |
Cough | ✓ | ✗ | ✓ | ✗ | ✗ | ✗ | ✗ | ✓ | ✓ | ✓ |
Sore throat | ✗ | ✓ | ✓ | ✗ | ✗ | ✗ | ✗ | ✓ | ✓ | ✗ |
Rhinorrhea | ✗ | ✓ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ | ✗ | ✗ |
Diarrhea | ✓ | ✗ | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✓ |
More than one sign or symptom | ✓ | ✓ | ✓ | ✗ | ✗ | ✗ | ✗ | ✓ | ✓ | ✓ |
Chest X-ray findings | ||||||||||
Only lung markings increased | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✗ | ✓ | ✗ | ✗* |
Chest computed tomography scan | ||||||||||
Mottling and ground-glass opacity | ✗ | ✓ | ✗ | ✗ | ✗ | ✓ | ✓ | ✓ | ✓ | ✗* |
Blood routine | ||||||||||
Leukocytes (× 109 l−1; normal range 5–12) | 12 | 4.6 | 7.9 | 4.7 | 7.8 | 8.8 | 4.0 | 7.8 | 10.8 | NA |
Neutrophils (× 109 l−1; normal range 2.0–7.2) | 9.24 | 3.21 | 6.48 | 1.97 | 1.08 | 2.76 | 1.99 | 5.1 | 1.23 | NA |
Lymphocytes (× 109 l−1; normal range 1.55–4.80) | 1.35 | 0.89 | 0.65 | 2.17 | 6.19 | 4.73 | 1.66 | 1.75 | 9.05 | NA |
Platelets (× 109 l−1; normal range 140–440) | 229 | 173 | 301 | 141 | 363 | 286 | 291 | 240 | 342 | NA |
Hemoglobin (g l−1; normal range 105–145) | 115 | 124 | 116 | 145 | 115 | 135 | 137 | 163 | 102 | NA |
Coagulation function | ||||||||||
APTT (s; normal range 28–45) | 43.1 | 46.9 | 42.1 | 45.8 | 40.5 | 35.3 | NA | NA | 41.5 | NA |
PT (s; normal range 11–15) | 13.5 | 14.4 | 13.1 | 15.3 | 12.1 | 13.3 | NA | NA | 13.6 | NA |
D-dimer (μg l−1; normal range <0.5) | 0.41 | 0.28 | 0.33 | 0.26 | 0.32 | 0.24 | 0.23 | 0.5 | 0.84 | NA |
Blood biochemistry | ||||||||||
Albumin (g l−1; normal range 40.0–55.0) | 44.6 | 47.9 | 39.8 | 44.5 | 45.1 | 46 | 48.3 | 48.2 | 39.5 | NA |
ALT (U l−1; normal range 9–50) | 20 | 6 | 11 | 11 | 31 | 21 | 14 | 17 | 172 | NA |
AST (U l−1; normal range 5–60) | 33 | 17 | 23 | 16 | 62 | 36 | 20 | 22 | 127 | NA |
Total bilirubin (μmol l−1; normal range 2.0–17.0) | 3.5 | 5.9 | 2.6 | 8.7 | 2.8 | 3.3 | 3.8 | 6.6 | 4.9 | NA |
BUN (mmol l−1; normal range 2.1–7.1) | 3.5 | 2.4 | 2.5 | 3.61 | 3.2 | 4.6 | 4.8 | 5.9 | 4.6 | NA |
Scr (μmol l−1; normal range 18–62) | 29 | 49 | 29 | 55 | 22 | 29 | 50 | 59 | 15 | NA |
CK (U l−1; normal range 45–390) | 117 | 64 | 71 | 64 | 278 | 75 | 113 | 103 | 112 | NA |
LDH (U l−1; normal range 159–322) | 217 | 165 | 217 | 138 | 379 | 252 | 218 | 203 | 367 | NA |
Glucose (mmol l−1; normal range 4.1–5.9) | 4.32 | 5.56 | 5.7 | 4.2 | 4.4 | 6.68 | 4.94 | 4.69 | 6.94 | NA |
Infection-related biomarkers | ||||||||||
Procalcitonin (ng ml−1; normal range <0.1) | 0.103 | 0.125 | 0.121 | <0.1 | <0.1 | <0.1 | <0.1 | 0.203 | 0.11 | NA |
ESR (mm h−1; normal range 0–15) | 25 | 4 | 6 | 2 | 33 | 2 | 20 | 7 | 2 | NA |
Serum ferritin (ng ml−1; normal range 22–322) | 84.6 | 63.6 | 58.2 | 178.4 | 9.5 | 47.4 | 73.9 | 304.4 | 919 | NA |
CRP (mg l−1; normal range 0.0–6.0) | 2.43 | 0.31 | 16.13 | 0.3 | 1.14 | 0.3 | 11.86 | 22.05 | 1.04 | NA |
